Pettinga Financial Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Pettinga Financial Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$202K	Sell	1,275 -3,886	-75%	-$525K	0.03%	148
2026 Q1	$659K	Sell	5,161 -9,355	-64%	-$1.17M	0.12%	91
2025 Q4	$1.77M	Sell	14,516 -4,024	-22%	-$461K	0.34%	52
2025 Q3	$1.86M	Buy	18,540 +795	+4%	+$71.6K	0.36%	51
2025 Q2	$1.47M	Sell	17,745 -10,915	-38%	-$871K	0.32%	50
2025 Q1	$2.32M	Sell	28,660 -245	-0.8%	-$21.9K	0.55%	43
2024 Q4	$2.6M	Buy	28,905 +3,297	+13%	+$319K	0.59%	40
2024 Q3	$2.53M	Sell	25,608 -1,025	-4%	-$101K	0.6%	35
2024 Q2	$2.47M	Buy	26,633 +193	+0.7%	+$17.3K	0.62%	36
2024 Q1	$2.51M	Sell	26,440 -405	-2%	-$37.6K	0.64%	38
2023 Q4	$2.4M	Buy	26,845 +8,030	+43%	+$596K	0.64%	39
2023 Q3	$1.37M	Buy	18,815 +475	+3%	+$37.9K	0.42%	40
2023 Q2	$1.53M	Sell	18,340 -870	-5%	-$72.8K	0.45%	38
2023 Q1	$1.46M	Buy	19,210 +960	+5%	+$79.7K	0.46%	38
2022 Q4	$1.51M	Sell	18,250 -2,020	-10%	-$164K	0.49%	39
2022 Q3	$1.61M	Buy	20,270 +3,295	+19%	+$278K	0.55%	37
2022 Q2	$1.26M	Buy	16,975 +4,525	+36%	+$340K	0.38%	45
2022 Q1	$1.12M	Buy	12,450 +1,985	+19%	+$183K	0.28%	52
2021 Q4	$1.17M	Buy	10,465 +4,823	+85%	+$582K	0.28%	54
2021 Q3	$709K	Buy	+5,642	New	+$727K	0.18%	61
2020 Q2	–	Sell	-7,070	Closed	-$548K	–	85
2020 Q1	$548K	Buy	+7,070	New	+$626K	0.37%	40
2019 Q4	–	Sell	-13,875	Closed	-$1.06M	–	93
2019 Q3	$1.06M	Buy	13,875 +10,325	+291%	+$858K	0.57%	37
2019 Q2	$311K	Buy	+3,550	New	+$303K	0.16%	75
2019 Q1	–	Sell	-9,000	Closed	-$646K	–	102
2018 Q4	$646K	Buy	+9,000	New	+$725K	0.42%	37

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Pettinga Financial Advisors's XBI Position: Q2 2026 in Review

Pettinga Financial Advisors reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 75% in Q2 2026, selling an estimated $525K and leaving 1,275 shares worth $202K. The position accounts for 0.03% of the portfolio, ranked #148.

Pettinga Financial Advisors first reported a position in XBI in Q4 2018 and has held it in 24 quarters since. The position peaked at $2.6M in Q4 2024. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Pettinga Financial Advisors held 1,275 shares of State Street SPDR S&P Biotech ETF worth $202K as of Q2 2026.
Pettinga Financial Advisors sold 3,886 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $525K.
State Street SPDR S&P Biotech ETF made up 0.03% of Pettinga Financial Advisors's portfolio in Q2 2026, its #148 holding.
Pettinga Financial Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2018 and has held it in 24 quarters since.
Pettinga Financial Advisors's State Street SPDR S&P Biotech ETF position peaked at $2.6M in Q4 2024.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Pettinga Financial Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.